ChatGPT Is Wowing Office Workers, Posing a Problem for Microsoft

Last spring, drugmaker Amgen Inc. announced plans to buy Microsoft Corp.’s Copilot AI assistant for 20,000 employees. It was a timely endorsement of the software company’s multibillion-dollar bet on generative artificial intelligence, and Microsoft touted its new Copilot customer in three separate case studies.

Thirteen months later, Amgen employees are using a rival product: OpenAI’s ChatGPT.

Amgen expanded its use of ChatGPT earlier this year after seeing the technology improve and hearing from employees that it helped with such tasks as research and summarizing scientific documents.

“OpenAI has done a tremendous job making their product fun to use,” said Senior Vice President Sean Bruich. Copilot is still ...